|
注册号: Registration number: |
ChiCTR2200066424 |
|
最近更新日期: Date of Last Refreshed on: |
2023-05-05 22:21:28 |
|
注册时间: Date of Registration: |
2022-12-05 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
新疆地区KSHV感染流行病学特征及影响因素研究 |
|
Public title: |
Epidemiological characteristics and influencing factors of KSHV infection in Xinjiang |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
新疆地区KSHV感染流行病学特征及影响因素研究 |
|
Scientific title: |
Epidemiological characteristics and influencing factors of KSHV infection in Xinjiang |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张景展 |
研究负责人: |
康晓静 |
|
Applicant: |
Jingzhan Zhang |
Study leader: |
Xiaojing Kang |
|
申请注册联系人电话: Applicant telephone: |
+86 17799199675 |
研究负责人电话:
Study leader's |
+86 13999927999 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jzhzhang@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
drkangxj666@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
新疆乌鲁木齐市天山区天池路91号 |
研究负责人通讯地址: |
新疆乌鲁木齐市天山区天池路91号 |
|
Applicant address: |
91 Tianchi Road, Tianshan District, Urumqi, Xinjiang |
Study leader's address: |
91 Tianchi Road, Tianshan District, Urumqi, Xinjiang |
|
申请注册联系人邮政编码: Applicant postcode: |
830001 |
研究负责人邮政编码: Study leader's postcode: |
830001 |
|
申请人所在单位: |
新疆维吾尔自治区人民医院 |
||
|
Applicant's institution: |
People’s Hospital of Xinjiang Uygur Autonomous Region |
||
|
研究负责人所在单位: |
新疆维吾尔自治区人民医院 |
||
|
Affiliation of the Leader: |
People’s Hospital of Xinjiang Uygur Autonomous Region |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY2022110101 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
新疆维吾尔自治区人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of People's Hospital of Xinjiang Uygur Autonomous Region |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-11-01 00:00:00 | ||
|
伦理委员会联系人: |
赵洋 |
||
|
Contact Name of the ethic committee: |
Yang Zhao |
||
|
伦理委员会联系地址: |
新疆乌鲁木齐市天山区天池路91号 |
||
|
Contact Address of the ethic committee: |
91 Tianchi Road, Tianshan District, Urumqi, Xinjiang |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 991 8563857 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
新疆维吾尔自治区人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
People’s Hospital of Xinjiang Uygur Autonomous Region |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
新疆乌鲁木齐市天山区天池路91号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
91 Tianchi Road, Tianshan District, Urumqi, Xinjiang |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
新疆维吾尔自治区自然科学基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Natural Science Foundation of Xinjiang Uygur Autonomous Region |
||||||||||||||||||||||
|
研究疾病: |
KSHV感染 |
||||||||||||||||||||||
|
Target disease: |
KSHV infected population |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
流行病学研究 |
||||||||||||||||||||||
|
Study type: |
Epidemilogical research |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
明确新疆地区人群中KSHV 感染血清阳性率,分析KSHV 感染危险因素,为KSHV 感染的预防及KSHV感染相关疾病研究提供基础。 |
||||||||||||||||||||||
|
Objectives of Study: |
To clarify the serum positive rate of KSHV infection in the population of Xinjiang, and analyze the risk factors of KSHV infection, so as to provide a basis for the prevention of KSHV infection and the study of KSHV infection related diseases. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
①存在精神异常或视力听力障碍等妨碍问卷调查正常进行的因素; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. There are mental disorders, vision and hearing impairment and other factors that hinder the normal progress of the questionnaire. 2. Refuse to participate in the informed consent process or cannot cooperate to complete the retention of blood and oral exfoliated cell samples. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-12-31 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-12-31 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Not applicable |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不涉及共享原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
No shared IPD involved |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
建立以微信小程序为载体的电子问卷系统采集并管理患者的基本社会人口学、家族史、生活方式、疾病史等信息。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
We set up an electronic questionnaire system with a WeChat applet to collect and manage patients' basic socio-demographic, family history, lifestyle, and disease history information. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |